Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:AOXGOTCMKTS:BIXTOTCMKTS:MBVXQOTCMKTS:STLTOTCMKTS:TRPXD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAOXGAoxing Pharmaceutical$0.01$0.01$0.00▼$0.02$2.86M7.0212,063 shs60,000 shsBIXTBioxytran$0.10-0.7%$0.13$0.06▼$0.23$9.39M1.79125,249 shs82,428 shsMBVXQMabVax Therapeutics$0.02$0.02$0.00▼$0.30N/AN/AN/A1,333 shsSTLTSpotlight Innovation$0.00$0.00▼$0.04N/AN/AN/A100 shsTRPXDTherapix Biosciences$0.00$2.75▼$22.40$299KN/A1,852 shs900 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAOXGAoxing Pharmaceutical0.00%0.00%-31.82%-21.05%+70.45%BIXTBioxytran0.00%-3.21%-28.43%-25.23%+9.44%MBVXQMabVax Therapeutics0.00%0.00%0.00%0.00%0.00%STLTSpotlight Innovation0.00%0.00%0.00%0.00%0.00%TRPXDTherapix Biosciences0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAOXGAoxing PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/ABIXTBioxytranN/AN/AN/AN/AN/AN/AN/AN/AMBVXQMabVax TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASTLTSpotlight InnovationN/AN/AN/AN/AN/AN/AN/AN/ATRPXDTherapix BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAOXGAoxing Pharmaceutical 0.00N/AN/AN/ABIXTBioxytran 0.00N/AN/AN/AMBVXQMabVax Therapeutics 0.00N/AN/AN/ASTLTSpotlight Innovation 0.00N/AN/AN/ATRPXDTherapix Biosciences 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAOXGAoxing PharmaceuticalN/AN/AN/AN/AN/AN/ABIXTBioxytranN/AN/AN/AN/A($0.02) per shareN/AMBVXQMabVax TherapeuticsN/AN/AN/AN/AN/AN/ASTLTSpotlight InnovationN/AN/AN/AN/AN/AN/ATRPXDTherapix BiosciencesN/AN/AN/AN/A$0.28 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAOXGAoxing PharmaceuticalN/AN/A0.00∞N/AN/AN/AN/AN/ABIXTBioxytran-$2.37M-$0.03N/A∞N/AN/AN/A-2,077.16%N/AMBVXQMabVax TherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/ASTLTSpotlight InnovationN/AN/A0.00N/AN/AN/AN/AN/AN/ATRPXDTherapix Biosciences-$4.79MN/A0.00N/AN/AN/AN/AN/AN/ALatest AOXG, TRPXD, BIXT, MBVXQ, and STLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025BIXTBioxytranN/A-$0.02N/A-$0.02N/AN/A4/3/2025Q1 2025BIXTBioxytranN/A-$0.01N/A-$0.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAOXGAoxing PharmaceuticalN/AN/AN/AN/AN/ABIXTBioxytranN/AN/AN/AN/AN/AMBVXQMabVax TherapeuticsN/AN/AN/AN/AN/ASTLTSpotlight InnovationN/AN/AN/AN/AN/ATRPXDTherapix BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAOXGAoxing PharmaceuticalN/AN/AN/ABIXTBioxytranN/AN/AN/AMBVXQMabVax TherapeuticsN/AN/AN/ASTLTSpotlight InnovationN/AN/AN/ATRPXDTherapix BiosciencesN/A0.49N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAOXGAoxing PharmaceuticalN/ABIXTBioxytranN/AMBVXQMabVax TherapeuticsN/ASTLTSpotlight InnovationN/ATRPXDTherapix Biosciences14.32%Insider OwnershipCompanyInsider OwnershipAOXGAoxing Pharmaceutical17.80%BIXTBioxytran70.00%MBVXQMabVax Therapeutics14.76%STLTSpotlight InnovationN/ATRPXDTherapix BiosciencesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAOXGAoxing Pharmaceutical350381.21 million313.35 millionNot OptionableBIXTBioxytran288.99 million26.70 millionNot OptionableMBVXQMabVax TherapeuticsN/AN/AN/ANot OptionableSTLTSpotlight Innovation4N/AN/ANot OptionableTRPXDTherapix Biosciences850,000N/ANot OptionableAOXG, TRPXD, BIXT, MBVXQ, and STLT HeadlinesRecent News About These CompaniesTRON (CRYPTO: TRX)February 13, 2024 | fool.comPaddle Healthy: TRX WorkoutSeptember 28, 2023 | mensjournal.comMDead: RAM 1500 TRXSeptember 24, 2023 | jalopnik.comJ2024 Ram 1500 TRX Final Edition Brings the EndSeptember 19, 2023 | autoweek.comAUsed 2010 Dodge Ram 1500 TRX trucks for sale near meAugust 12, 2023 | cars.comCT. Rowe Price Retirement I 2040 IFebruary 23, 2023 | morningstar.comMUsed 2022 RAM 1500 TRX trucks for sale in Dallas, TXFebruary 18, 2023 | cars.comCThe 2023 Chevy Silverado ZR2 Is More Well-Rounded Than the Raptor or TRXJanuary 1, 2023 | jalopnik.comJ2022 Ram 1500 TRXOctober 25, 2022 | caranddriver.comCTRX-Duo Is A Red Pitaya Clone For Software Defined RadioOctober 13, 2022 | hackaday.comHMedia Sentiment Over TimeAOXG, TRPXD, BIXT, MBVXQ, and STLT Company DescriptionsAoxing Pharmaceutical OTCMKTS:AOXG$0.0075 0.00 (0.00%) As of 09:30 AM EasternAoxing Pharmaceutical Company, Inc. a specialty pharmaceutical company, engages in research and development, manufacture, and distribution of narcotic, pain-management, and addiction treatment pharmaceutical products primarily in the People's Republic of China. The company's principal products include Zhongtong'an, a capsule of herbal extraction for the indication of oral and dental pain; and Yiqi Qiangshen Granule, an OTC herbal extraction for tonifying qi and empowering body, and promoting blood circulation to remove meridian obstruction, as well as Tilidine hydrochloride, an orally-absorbed synthetic narcotic analgesic tablet used in 50mg or 100mg dosage for relief of acute, moderate to severe pain, and chronic cancer-related pain. Its products under development comprise Oxycodone and Acetaminophen tablets and capsules, which has completed clinical trials for the treatment of acute and chronic pain; Buprenorphine/Naloxone, a sublingual combo tablet that has completed Phase II clinical trials for the treatment of opioid dependence; and Tilidine/Naloxone, a compound capsule which is in Phase II clinical trial to treat acute and chronic pain. The company was formerly known as China Aoxing Pharmaceutical Company, Inc. and changed its name to Aoxing Pharmaceutical Company, Inc. in March 2010. Aoxing Pharmaceutical Company, Inc. is headquartered in Shijiazhuang, China.Bioxytran OTCMKTS:BIXT$0.10 0.00 (-0.66%) As of 03:22 PM EasternBioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts.MabVax Therapeutics OTCMKTS:MBVXQ$0.02 0.00 (0.00%) As of 03/19/2020MabVax Therapeutics Holdings, Inc. is a clinical-stage drug development company. It is focused on discovering and developing small molecule drugs to treat cancer. TELINTRA is the Company's lead small molecule product candidate in clinical development for the treatment of blood disorders, including cancer. MabVax Therapeutics Holdings, Inc., formerly known as Telik, Inc., is based in San Diego, California.Spotlight Innovation OTCMKTS:STLTSpotlight Innovation Inc., a pharmaceutical company, acquires and develops proprietary therapies to address unmet medical needs with an emphasis on rare, emerging, and neglected diseases. It identifies in-licensing opportunities and manages product development through partnerships with universities, medical schools, contract research organizations, and contract manufacturing organizations, as well as pursues product commercialization opportunities, including out-licensing and strategic partnerships. The company is developing Crotoxin, which is in Phase I clinical study for the treatment of cancer. It also develops various compounds for the treatment of viral infections, including Zika virus infection; and products derived from cobra venom to treat chronic pain. Spotlight Innovation Inc. has a license agreement with Indiana University Research and Technology Corporation to commercialize STL-182, an orally-available small molecule that might have therapeutic potential for treating spinal muscular atrophy. The company is based in Urbandale, Iowa.Therapix Biosciences OTCMKTS:TRPXDTherapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110, which has completed Phase II a clinical trial for the treatment of Tourette syndrome and Obstructive Sleep Apnea; THX-160, which has completed two preliminary preclinical studies for the treatment of acute and chronic pain; and THX-210 for the treatment of autism spectrum disorder and epilepsy. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Givatayim, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
